AI-guided Immunotherapy Choice for Liver Cancer
Part of Cancer clinical trials.
This study uses an artificial intelligence (AI) tool to help doctors choose the best first-line immunotherapy for your liver cancer. It aims to see if the AI's recommendation improves treatment outcomes compared to standard selection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a confirmed diagnosis of hepatocellular carcinoma (a type of liver cancer)
- Your liver cancer must be unresectable (cannot be removed with surgery) and you need systemic therapy as your first treatment
- You must not have received any prior systemic therapy for this cancer
- You must have good liver function (Child-Pugh class A) and be in generally good physical condition (ECOG 0 or 1)
- You must be able to have CT or MRI scans of your tumor before starting treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This study uses artificial intelligence (AI) to analyze your CT or MRI scans and help predict how well immunotherapy might work for your liver cancer. The goal is to find better ways to match you with the right treatment and improve your outcomes.
This study tests whether an artificial intelligence system can help doctors find and treat liver cancer if it comes back after your first surgery or ablation. It focuses on early detection and providing another curative treatment if a recurrence is found.
This study uses an AI tool to predict how liver cancer might come back after surgery. It is for people with early-stage liver cancer who are already scheduled for surgery and have recent MRI scans.
This trial uses artificial intelligence to help doctors better stage (classify the severity of) and plan treatment for hepatocellular carcinoma, a type of primary liver cancer. Researchers will collect your clinical information and imaging to see if AI can improve decision-making about your care.
This study uses artificial intelligence to look at your liver cancer's environment and predict how well it might respond to a combination treatment called TACE (which blocks blood flow to the tumor) plus immunotherapy and targeted therapy. It aims to help personalize your care by better understanding your tumor.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.